Karo Bio Obtains Rights to A-348441 and Selected Compounds from Abbott Laboratories for the Treatment of Diabetes
November 13, 2003 02:43 ET
|
Karo Bio
HUDDINGE, Sweden, Nov. 13, 2003 (PRIMEZONE) -- Karo Bio today announced that the company immediately will obtain rights to technologies, lead compounds and preclinical data from its joint diabetes...
Karo Bio -- Quarterly report July -- September 2003
October 15, 2003 02:47 ET
|
Karo Bio
HUDDINGE, Sweden, Oct. 15, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF):
-- Merck & Co., Inc. has decided to discontinue the development of one compound in the collaboration. A second...
Promising Data from Karo Bio -- Demonstrate Potential for New Way to Treat Obesity
August 21, 2003 03:39 ET
|
Karo Bio
HUDDINGE, Sweden, August 21, 2003 (PRIMEZONE) -- Scientists from Karo Bio (Other OTC:KARBF), together with scientific collaborators, have for the first time shown results that may offer a new...
Karo Bio updates status of compound from Merck collaboration
August 19, 2003 02:40 ET
|
Karo Bio
HUDDINGE, Sweden, August 19, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF) announces today that Merck & Co, Inc. (NYSE:MRK) has decided to discontinue development of the first of the two...
Karo Bio Quarterly Report April - June 2003
July 15, 2003 02:48 ET
|
Karo Bio
HUDDINGE, Sweden, July 15, 2003 (PRIMEZONE) -- Karo Bio Quarterly Report April - June 2003
- A second preclinical milestone reached and milestone payment received in the Merck collaboration.
-...
Karo Bio, a Leader in Nuclear Receptor Research and Drug Discovery, will be Discussing the Company's Program Successes and New Partnering Opportunities at the Upcoming Bio 2003 Annual Conference, June 22-26, 2003
June 05, 2003 10:41 ET
|
Karo Bio
HUDDINGE, Sweden, June 5, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF), one of the leading biotechnology companies in Europe, will be attending the BIO 2003 Convention, the largest annual biotech...
Milestone Reached in the Karo Bio - Merck & Co., Inc. Collaboration
May 08, 2003 03:05 ET
|
Karo Bio
HUDDINGE, Sweden, May 8, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF):
A significant preclinical milestone has been achieved in the estrogen receptor collaboration between Merck & Co., Inc...
Karo Bio: Quarterly Report January - March 2003
April 23, 2003 02:52 ET
|
Karo Bio
HUDDINGE, Sweden, April 23, 2003 (PRIMEZONE) -- Karo Bio (Other OTC:KARBF):
-- A novel first-in-class compound for type 2 diabetes has been
identified in the collaboration with Abbott...
Karo Bio's Annual General Meeting
April 10, 2003 02:40 ET
|
Karo Bio
HUDDINGE, Sweden, April 10, 2003 (PRIMEZONE) -- At Karo Bio AB's (Other OTC:KARBF) Annual General Meeting on Wednesday April 9, 2003 the following was resolved.
Dividend
No dividend is to be paid...
Abbott Laboratories and Karo Bio Identify Novel new Compound for Diabetes
March 27, 2003 03:06 ET
|
Karo Bio
HUDDINGE, Sweden, March 27, 2003 (PRIMEZONE) -- Abbott Laboratories and Karo Bio AB (Other OTC:KARBF) today announced that they have identified a novel, first-in-class compound, A-348441, for the...